Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension studyHeinz Gisslinger, Jiřı́ Schwarz, Árpád Illés et al.|The Lancet Haematology|2020Cited by 351
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment optionsJean‐Jacques Kiladjian, Christoph Klade, Francisca Ferrer‐Marín et al.|Annals of Hematology|2024Cited by 14
ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment OptionsJean‐Jacques Kiladjian, Christoph Klade, Francisca Ferrer‐Marín et al.|Blood|2024Cited by 0
Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia veraVeronika Buxhofer‐Ausch, Steffen Koschmieder, Andreas Reiter et al.|Blood|2025Cited by 0